Charles River Laboratories's results for Q3 2026 (quarter ended September 26, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-04. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $983 million (−2.2% vs a year earlier) |
| Diluted EPS (GAAP) | $6.86 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $3.09 |
| Full-year guidance | Raised |
Guidance
Charles River raised 2026 guidance: non-GAAP EPS to $11.35-11.55 from $11.15-11.45 and organic revenue growth to at least 1.5%.
Why this label: 'increasing its 2026 revenue and earnings per share guidance'; CURRENT vs PRIOR table shows revenue growth and EPS up.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| non-GAAP EPS | FY2026 | $11.35–11.55 | $11.15–11.45 |
| GAAP EPS | FY2026 | $8.15–8.35 | $3.05–3.35 |
| reported revenue growth | FY2026 | (2.0)% to (1.5)% | (3.5)% to (2.5)% |
| organic revenue growth | FY2026 | at least +1.5% | 0.0% to 1.0% |
From the release
Revenue: "Total revenue · 982,732 · 1,004,852"
Earnings per share: "Reports third-quarter revenue of $982.7 million, GAAP earnings per share of $6.86, and non-GAAP earnings per share of $3.09."
non-GAAP EPS: "Non-GAAP EPS estimate · $11.35 – $11.55 · $11.15 – $11.45"
GAAP EPS: "GAAP EPS estimate · $8.15 – $8.35 · $3.05 – $3.35"
reported revenue growth: "Revenue growth/(decrease), reported · (2.0)% - (1.5)% · (3.5)% - (2.5)%"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Charles River raised 2026 non-GAAP EPS guidance to $11.35-$11.55 after 4.7% organic growth
Source
Charles River Laboratories earnings release (SEC filing), accession 0001100682-26-000156, filed 2026-11-04.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.